Clinical trials: Melanoma Stage
Cancer, Lung Cancer
Social Prescriptions and Micro-Learning to Improve Care for Cancer Patients and Their Support Persons
Optimal patient-centered care is often not being delivered to cancer patients, especially to vulnerable populations like those living in underserved rural areas.
- Conditions
- Cancer, Lung Cancer, Colorectal Cancer, Hematological Cancer
- Trial name
- PRISMA (NCT07788729)
- Testing
- PRISMA-interventions
- Where
- 8 sites in Germany
- Volunteers
- 384 people, healthy volunteers welcome
- Sponsor
- University of Regensburg
Cancer
Heparin or M-EDTA in Preventing Catheter-Related Infections and Blockages in Patients at High Risk for a Catheter-Related Infection
RATIONALE: Heparin or M-EDTA may prevent catheter-related infections and blockages in patients at high risk for a catheter-related infection.
- Trial name
- NCT00378781
- Testing
- Heparin, Minocycline-EDTA
- Sponsor
- M.D. Anderson Cancer Center
Melanoma (Skin)
Vaccine Therapy in Treating Patients With Stage IIB, Stage IIC, Stage III, or Stage IV Melanoma
RATIONALE: Vaccines made from DNA may make the body build an effective immune response to kill tumor cells. PURPOSE: This randomized phase I trial is studying the side effects and best dose of vaccine therapy in treating patients…
- Trial name
- NCT00104845
- Testing
- human gp100 plasmid DNA vaccine, mouse gp100 plasmid DNA vaccine
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
The purpose of this study is to determine the safety, tolerability, and preliminary efficacy of INCAGN02385 in participants with advanced malignancies.
- Conditions
- Cervical Cancer, Microsatellite Instability (MSI)-High Endometrial Cancer, Gastric Cancer (Including Stomach and Gastroesophageal Junction [GEJ]), Esophageal Cancer
- Trial name
- NCT03538028
- Testing
- INCAGN02385
- Where
- 4 sites in United States
- Volunteers
- 22 people
- Sponsor
- Incyte Biosciences International Sàrl
Melanoma
IVAC MUTANOME Phase I Clinical Trial
Clinical first-in-human study evaluating the safety, tolerability and immunogenicity of intra-nodal administration of a personalized vaccination with IVAC MUTANOME vaccine with or without initial treatment with RBL001/RBL002…
- Trial name
- NCT02035956
- Testing
- IVAC MUTANOME, RBL001/RBL002
- Where
- 3 sites in Austria, Germany
- Volunteers
- 15 people
- Sponsor
- BioNTech RNA Pharmaceuticals GmbH
Melanoma, Sarcoma
A Phase 1 Study of Mixed Bacteria Vaccine (MBV) in Patients With Tumors Expressing NY-ESO-1 Antigen
This was a phase 1, open-label, multiple dose, single-arm study. The mixed bacteria vaccine (MBV) was administered at a starting dose of 250 EU (1 µL) and escalated in each subject to a dose inducing the desired pyrogenic effect…
- Conditions
- Melanoma, Sarcoma, Gastrointestinal Stromal Tumor (GIST), Head and Neck Cancer
- Trial name
- NCT00623831
- Testing
- Mixed bacterial vaccine
- Where
- Germany
- Volunteers
- 17 people
- Sponsor
- Ludwig Institute for Cancer Research
Stage IV Melanoma, Advanced Lung Cancer
Improving Patient and Caregiver Understanding of Risks and Benefits of Immunotherapy for Advanced Cancer
The purpose of this study is to refine and pilot test educational material developed to educate and support patients receiving immunotherapy for advanced cancer.
- Conditions
- Stage IV Melanoma, Advanced Lung Cancer, Stage IV Non-Small Cell Lung Cancer, Unresectable Non-Small Cell Lung Carcinoma
- Trial name
- UPLIFT (NCT04670445)
- Testing
- Educational Video and QPL List, Usual Care
- Where
- United States
- Volunteers
- 199 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Stage III or IV Melanoma
Phase 1 Biomarker Study of Anti-PDL-1 in Advanced Melanoma
The purpose of this study is to evaluate pharmacodynamic changes of BMS-936559 treatment on the biomarkers measured in the peripheral blood and tumor tissues of subjects with unresectable Stage III or IV Melanoma.
- Trial name
- PD-L1 (NCT01455103)
- Testing
- BMS-936559 (Anti-PD-L1)
- Sponsor
- Bristol-Myers Squibb
Stage IIIC Skin Melanoma, Stage IV Skin Melanoma
A Clinical Trial: Adjuvant Low-dose Ipilimumab + Nivolumab After Resection of Melanoma Macrometastases
Nivolumab (OpdivoTM, BMS), a human IgG-4 anti-PD-1 monoclonal antibody has demonstrated anti-tumor activity in patients with advanced melanoma.
- Trial name
- ipniv (NCT02941744)
- Testing
- nivolumab, ipilimumab
- Where
- Belgium
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Universitair Ziekenhuis Brussel
Recurrent Melanoma, Stage IIIA Melanoma
High-Dose Aldesleukin and Ipilimumab in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed By Surgery
This phase II trial studies how well high-dose aldesleukin and ipilimumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery.
- Conditions
- Recurrent Melanoma, Stage IIIA Melanoma, Stage IIIB Melanoma, Stage IIIC Melanoma
- Trial name
- NCT02203604
- Testing
- aldesleukin, ipilimumab, laboratory biomarker analysis
- Where
- 6 sites in United States
- Volunteers
- 9 people
- Sponsor
- CINJRegulatory
Melanoma Stage III, Melanoma Stage IV
A Study to Investigate the Novel Agent BNT111 and Cemiplimab in Combination or as Single Agents in Patients With Advanced Melanoma That Has Not Responded to Other Forms of Treatment
This is an open-label, randomized, multi-site, Phase II, interventional trial designed to evaluate the efficacy, tolerability, and safety of BNT111 + cemiplimab in anti-programmed death protein 1 (PD-1)/anti-programmed death…
- Conditions
- Melanoma Stage III, Melanoma Stage IV, Unresectable Melanoma
- Trial name
- NCT04526899
- Testing
- BNT111, Cemiplimab
- Where
- 49 sites in United States, Australia and 5 more
- Volunteers
- 184 people
- Sponsor
- BioNTech SE
Patients at Risk for Melanoma
Oral N-acetylcysteine for Protection of Human Nevi Against UV-induced Oxidative Stress/Damage in Vivo
This is a phase II intervention to propose a new melanoma chemoprevention agent. The investigators believe oxidative stress/damage in nevi is a probable indication for melanoma risk, and propose that reduced melanoma risk in…
- Trial name
- NCT01612221
- Testing
- N-acetylcysteine
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- University of Utah
Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8
A Study on How to Safely Guide Surgery for Melanoma and Similar Skin Tumors in Children Using Pathology and Genetic Information
This phase II trial compares the effect of using risk-based stratification to guide surgical management to the usual approach in treating cutaneous melanoma, atypical Spitz/Spitzoid tumors or other atypical melanocytic tumors…
- Conditions
- Clinical Stage 0 Cutaneous Melanoma AJCC v8, Clinical Stage I Cutaneous Melanoma AJCC v8, Clinical Stage II Cutaneous Melanoma AJCC v8, Cutaneous Melanocytic Neoplasm
- Trial name
- NCT07621614
- Testing
- Biospecimen Collection, Chest Radiography, Computed Tomography
- Where
- 13 sites in United States
- Volunteers
- 51 people
- Sponsor
- Children's Oncology Group
Vascular Malformations, Arteriovenous Malformations
A Study to Evaluate the Efficacy and Safety of Everolimus in Patients With Teratment-refractory Vascular Anomalies
Background and Objectives Vascular anomalies are a heterogeneous group of disorders classified into vascular tumors and vascular malformations according to the ISSVA classification.
- Conditions
- Vascular Malformations, Arteriovenous Malformations, Venous Malformation, Lymphangioma
- Trial name
- NCT07477548
- Testing
- Everolimus
- Volunteers
- 67 people
- Sponsor
- Yonsei University
Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma
Vaccine Therapy With or Without Sargramostim in Treating Patients Who Have Undergone Surgery for Melanoma
This randomized phase II trial is studying vaccine therapy and sargramostim to see how well they work compared to vaccine therapy alone in treating patients who have undergone surgery for stage IIB, stage IIC, stage III, or stage…
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Stage IIB Melanoma
- Trial name
- NCT00089063
- Testing
- tyrosinase peptide, gp100 antigen, MART-1 antigen
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- National Cancer Institute (NCI)
Metastatic Melanoma, Squamous Cell Skin Carcinoma
MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma
This is a Phase 1b open-label dose escalation trial of Ad/MG1-MAGEA3 and Pembrolizumab in patients with Metastatic Melanoma or Cutaneous Squamous Cell Skin Cancer that has failed prior standard of care treatments.
- Trial name
- Pelican (NCT03773744)
- Testing
- Ad-MAGEA3, MG1-MAGEA3, Pembrolizumab
- Sponsor
- Turnstone Biologics, Corp.
Melanoma (Skin), Melanoma, Uveal
Tebentafusp in Molecular Relapsed Disease (MRD) Melanoma
Researchers are trying to find ways to improve the management of people with intermediate or high risk resected cutaneous melanoma or with primary uveal melanoma.
- Trial name
- TebeMRD (NCT05315258)
- Testing
- Tebentafusp
- Where
- 10 sites in United Kingdom
- Volunteers
- 850 people
- Sponsor
- University of Oxford
Advanced Solid Tumors
A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors
To better understand the safety and tolerability of ALKS 4230 in humans
- Trial name
- NCT02799095
- Testing
- ALKS 4230, ALKS 4230 + pembrolizumab
- Where
- 31 sites in United States, Australia and 5 more
- Volunteers
- 243 people
- Sponsor
- Mural Oncology, Inc
Melanoma, Skin Cancer
Radiation, Chemotherapy, Vaccine and Anti-MART-1 and Anti-gp100 Cells for Patients With Metastatic Melanoma
Background: Melanoma antigen recognized by T-cells (MART-1) and gp100 are two genes found in melanoma cells. An experimental procedure developed for treating patients with advanced melanoma uses these genes and a type of virus to…
- Trial name
- NCT00923195
- Testing
- MART-1: 26-35(27L) Peptide, Montanide ISA 51 VG, gp100:154-162 Peptide
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- National Cancer Institute (NCI)
Solid Tumor, Adult, Advanced Solid Tumor
A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
Phase 1/2 study to evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of SNS-101, a novel anti VISTA IgG1 monoclonal antibody as monotherapy or in combination with cemiplimab in patients with…
- Conditions
- Solid Tumor, Adult, Advanced Solid Tumor, Head and Neck Cancer, Breast Cancer
- Trial name
- NCT05864144
- Testing
- SNS-101 (anti-VISTA), Cemiplimab
- Where
- 10 sites in United States
- Volunteers
- 98 people
- Sponsor
- Sensei Biotherapeutics, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.